COPENHAGEN, DENMARK, December 2nd, 2020 – Biograil ApS, a Copenhagen based biotech company developing a unique oral device for delivery of therapeutics that would otherwise be administered by injection, has signed a Feasibility, Option and License Agreement with Janssen Biotech, Inc., one of the Janssen Pharmaceutical Companies of Johnson & Johnson. The collaboration was facilitated by Johnson & Johnson Innovation.
Under the agreement, Janssen and Biograil will work together to advance BIONDDTM, the Biograil drug delivery technology, seeking to achieve effective oral absorption/distribution for therapeutics which cannot be absorbed from an ordinary tablet or capsule. Such therapeutics may include large biological molecules, antibodies, peptides, and oligonucleotides. Financial terms of the agreement were not disclosed.
Biograil CEO Karsten Lindhardt said: “We look forward to working with Janssen to optimize the design of our delivery device and evaluate its application to oral delivery of several potential therapeutic products. We see this agreement as a major step forward for Biograil and our BIONDD platform”
About Biograil ApS
Biograil is a Danish start-up using injection molding to manufacture a device contained in a standard size capsule able to deliver active substances into the gastrointestinal wall. The team behind Biograil is a combination of seasoned entrepreneurs with long experience in creating successful biotech companies as well as R&D executives behind the world’s first injection molded oral tablet approved by the FDA. Initial funding for Biograil was completed in late 2019 and led by HTGF of Germany, and included Megatrend of Denmark, Investiere of Switzerland, and Sanner Ventures of Germany.